Peter Reichardt

Helios Hospital Berlin-Buch — Germany

Medicine · Health Sciences

83h-index34.3kcitations639works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gastrointestinal Tumor Research and Treatment(253), Sarcoma Diagnosis and Treatment(246), Gastric Cancer Management and Outcomes(163), Gastrointestinal disorders and treatments(75), Chronic Myeloid Leukemia Treatments(60)

Publications638 total

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With <i>KIT</i> Exon 9 Mutations
JAMA Oncology·2026Open Access
Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)
Journal of Cancer Research and Clinical Oncology·2026Open Access
Malignome der Weichteile und der Knochen
Elsevier eBooks·2026
Supplementary Figure S3 from &lt;i&gt;KIT&lt;/i&gt; and &lt;i&gt;PDGFRA&lt;/i&gt; Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Study Protocol from &lt;i&gt;KIT&lt;/i&gt; and &lt;i&gt;PDGFRA&lt;/i&gt; Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Figure S2 from &lt;i&gt;KIT&lt;/i&gt; and &lt;i&gt;PDGFRA&lt;/i&gt; Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Figure S1 from &lt;i&gt;KIT&lt;/i&gt; and &lt;i&gt;PDGFRA&lt;/i&gt; Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Table S1 from &lt;i&gt;KIT&lt;/i&gt; and &lt;i&gt;PDGFRA&lt;/i&gt; Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
2025Open Access
Supplementary Table S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Data from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Supplementary Table S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Supplementary Table S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025· 1 citedOpen Access
Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
2025Open Access
Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Clinical Cancer Research·2025
1638 The Sarcoma Ring Trial: A case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
Radiotherapy and Oncology·2025
Correction: The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
Journal of Cancer Research and Clinical Oncology·2025Open Access
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024)
Geburtshilfe und Frauenheilkunde·2025
page 1 of 32Next →

Frequent Co-authors

Jean‐Yves Blay(23), Peter Hohenberger(20), Paolo G. Casali(17), Mikael Eriksson(16), Hans Gelderblom(16), Heikki Joensuu(16), Kirsten Sundby Hall(16), Sebastian Bauer(15), Stefan Bielack(15), Alessandro Gronchi(13), Piotr Rutkowski(13), Patrick Schöffski(13), Sylvie Bonvalot(11), Eva Wardelmann(11), Ian Judson(10), Angelo Paolo Dei Tos(10), Giovanni Grignani(10), Robin L. Jones(10), Bernd Kasper(10), Axel Le Cesne(10)